Peter Lynch · Growth at a reasonable price (GARP)
Is Royalty Pharma plc (RPRX) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
58/100
Mixto
2/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a RPRX
PEG ≤ 1.0
clave2.33
EPS CAGR ≥ 15%
clave11.8%
Revenue CAGR ≥ 10%
1.0%
Net margin > 0
33.9%
Cómo se valora RPRX en otras estrategias
Datos financieros en vivo
Cap. mercado
$32.74B
PER (TTM)
27.6x
ROIC (TTM)
8.43%
Margen bruto
99.95%
Otros análisis Peter Lynch
Preguntas frecuentes
What is RPRX's Peter Lynch fit score?
RPRX scores 58/100 on our Peter Lynch fit engine. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own RPRX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends RPRX.
How often is this score updated?
RPRX's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende RPRX personalmente.
